$ATTO

Attovia Therapeutics, Inc.

Attovia Therapeutics is a clinical-stage biopharmaceutical company based in San Carlos, California, that develops biotherapeutics for immune-mediated diseases. Its ATTOBODY platform supports candidates including ATTO-1310, which targets IL-31 for chronic pruritic conditions, and ATTO-2306, which targets IL-13 and IL-31 for atopic dermatitis and other immune-mediated skin diseases. ATTO-1091 targets TL1A, IL-23, and integrin α4β7 for inflammatory bowel disease.

AlphAI earnings readSecond quarter 2026 · SEP 2Attovia Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate UpdateVerdict: solid

Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.

No enriched coverage for $ATTO in the last 7 days.

No SEC Form 4 filings for $ATTO in the last 30 days.

See all $ATTO insider activity →

Attovia Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update

Attovia Therapeutics, Inc. (ATTO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Attovia Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update Announced positive topline 12-week Phase 1b results for ATTO-1310 in patients with chronic pruritus (CP) and high-itch atopic dermatitis (AD) Initiation of global Phase

ATTO sentiment & insider activity

Recent ATTO coverage spans financial news, earnings and technology.

What's driving ATTO

  • Citigroup kept its Buy rating on Attovia Therapeutics and increased its price target to $34 from $30, suggesting a 113% upside from the Nov 9 close of $15.96, according to the bank.

    tradingview.com · Nov 10, 2026

  • Morgan Stanley kept its Overweight rating on Attovia Therapeutics and increased its price target to $40 from $39, a 2.6% rise. This target suggests a 150.6% upside from the Nov 9 closing price of $15.96, according to the firm.

    tradingview.com · Nov 10, 2026

  • Clinical efficacy and next-stage trial initiation improve the probability-weighted outlook for ATTO-1310, while the cash runway reduces near-term financing risk.

    SEC EDGAR 8-K · Nov 9, 2026

  • Positive Phase 1b results could boost investor confidence and drive the stock higher.

    investing.com · Nov 5, 2026

  • Potential upside of ~24% from current price may attract buyers.

    theglobeandmail.com · Sep 5, 2026

AlphAI scores every news story that mentions ATTO with an AI model for sentiment and relevance, and aggregates insider trades from Attovia Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $ATTO

Score
$ATTOMedEarnings

Attovia Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update

Attovia Therapeutics, Inc. (ATTO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Attovia Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update Announced positive topline 12-week Phase 1b results for ATTO-1310 in patients with chronic pruritus (CP) and high-itch atopic dermatitis (AD) Initiation of global Phase

$ATTOHighAI 9/10

Attovia reports 12-week data from ATTO-1310 itch therapy trial

Attovia Therapeutics (NASDAQ:ATTO) reported 12-week Phase 1b trial results for ATTO-1310, an anti-IL-31 therapy. In chronic pruritus patients, 82% of treated patients saw a 4-point reduction in itch versus 22% with placebo. In high-itch atopic dermatitis patients, 44% of treated patients achieved a 4-point reduction versus 75% with placebo. The drug was generally well-tolerated, with plans for Phase 2 trials in 2027.

$ATTOMedAI 8/10Earnings

Attovia Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

Attovia Therapeutics, Inc. (ATTO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Attovia Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update ATTO-1310 demonstrated preliminary clinical proof of concept in chronic pruritus and high-itch atopic dermatitis (AD); complete Phase 1b data expected in Q4 2026 Phase 2 studies of

Deere upgraded, Lumentum initiated: Wall Street's top analyst calls

Analysts upgraded Deere (DE) to Outperform with a $800 target, citing strong North American demand. Abercrombie & Fitch (ANF) was upgraded to Buy with a $162 target after Q2 earnings beat. Agco (AGCO) upgraded to Outperform with a $150 target, expecting 2027 volume recovery. Kaiser Aluminum (KALU) upgraded to Buy with a $184 target. Stag Industrial (STAG) upgraded to Outperform. PG&E (PCG) downgraded by Wells Fargo and BMO. Mizuho downgraded PG&E, Sempra Energy (SRE), and Edison International (E

$ATTOMedAI 8/10

Wall Street analysts bullish on Attovia as itch drug data fuel biotech optimism

Attovia Therapeutics received bullish ratings from Citi, Morgan Stanley, and RBC, with price targets ranging from $30 to $45, citing promising early data for its chronic-itch drug ATTO-1310 and its antibody platform. The stock, trading around $21, has significant upside potential according to analysts. The company has $420M in cash post-IPO, reducing near-term financing concerns. Analysts caution about clinical-stage risks, including trial outcomes and competition.

Related tickers